Broadcast Date: 
  • Time: 

The poor translatability of early-stage preclinical models is a major setback in oncology drug development, and inter patient tumor heterogeneity is also a significant hurdle. Patient-derived xenografts (PDXs) are the gold standard in vivo models for their proven clinical relevance to human disease. Unraveling the biological processes driving tumor resistance to treatments, including KRAS inhibitors and checkpoint inhibitors, is necessary to support the development of targeted treatment strategies and model resistance to standard and new therapeutics. Pretreated PDX models, derived directly from tumors of patients who received known treatments before sample collection, have promising applications for precision medicine. 

In this webinar, two experts will share their perspectives on pretreated PDX models. Dr. Anthony Tolcher (NEXT OncologyTM) will share the clinical history of patients with multiple lines of treatment, including their importance and value to the development of translational PDX models. Dr. Rekha Pal (Crown Bioscience) will discuss the establishment of pretreated PDX models and their applications for the development and testing of next-generation drug candidates.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

Anthony Tolcher
Anthony W. Tolcher, MD, FRCPS(C), FACP, FASCO
CEO and Founder
NEXT Oncology

Rekha Pal
Rekha Pal, PhD
Crown Bioscience

Crown logo green


Comments are closed.